Biomimesys
A chemotaxis-based explanation of spheroid formation in 3D cultures of breast cancer cells
New results of growing of breast cancer (MCF7 and MCF7-sh-wisp2) cells in BIOMIMESYS® Adipose tissue as a relevant 3D in vitro model, using Keller–Segel PDE system to model chemotactical auto-organization of cells. Abstract Three-dimensional cultures of cells are gaining popularity as an in vitro improvement over 2D Petri dishes. In many such experiments, Read more…
Application Notes
Simplifying 3d cell culture generation for high content screening with BIOMIMESYS® and the Viaflo 96-384 (with Integra Biosciences)
Growing interest in phenotypic screening, together with evidence that the drug response of cells grown in three-dimensional (3D) structures more closely resembles in vivo activity, has made high throughput, 3D fluorescence imaging an attractive screening option for drug discovery. However, creating 3D spheroids compatible with high content screening can be Read more…
Biomimesys
Meryl defended his doctoral thesis about pluripotent stem cells, liver and BIOMIMESYS®
We are very pleased to announce that Meryl, our first CIFRE PhD student, defended his doctoral thesis last week! His PhD work was dealing with the use of pluripotent stem cells to study liver diseases. He has also developed an innovative model to obtain liver organoïds in our BIOMIMESYS® product. Read more…
Biomimesys
New 384-well plates format for BIOMIMESYS® Liver & Oncology entitling Cell-Based Assays High-Throughput Screening
HCS-Pharma is pleased to launch BIOMIMESYS® Liver and Oncology in ready-to-use 384-well plate format for screening applications. Adopt BIOMIMESYS® 3D cell culture systems and obtain more predictive in vitro models. You can find our presentations in PDF format for BIOMIMESYS® Liver for BIOMIMESYS® Oncology For more information, contact us at hello@biomimesys.com
Biomimesys
Impact of neurodegenerative diseases on extracellular space organization and diffusion through hyaluronan remodeling
Soria et al. has published this year an interesting study about the modification leading by synucleopathy on the nanoscale organization and diffusivity of the extracellular space, through hyaluronan remodeling. Indeed the extracellular space (ECS), composed by the interstitial fluid and the extracellular matrix (ECM), plays several roles in health and Read more…
Biomimesys
An innovative three dimension (3D) cell culture system mimicking in vivo conditions
HCS Pharma is pleased to present the whole range of BIOMIMESYS® Products. All our scientific team is ready to support you in using our 3D organ/tissue-specific cell-culture technology. Rediscover your cells in real in vitro 3D-culture conditions with our special evaluation plate format . You can find our presentation in Read more…
Biomimesys
3D co-culture of dopaminergic neurons and astrocytes in BIOMIMESYS® Brain to study Parkinson’s disease
Parkinson’s disease affects more than 6 million people worldwide. This neurodegenerative disease is characterized by the death of dopaminergic neurons in the substantia nigra pars compacta, with intracellular accumulation of alpha-synuclein aggregates known as Lewi bodies. This neuronal loss leads to a decrease in the neurotransmitter dopamine that cause mainly Read more…
Biomimesys
Our involvement in preclinical breast cancer research
On the occasion of the breast cancer awareness month, HCS Pharma is willing to thank all researchers working in the field to better understand the pathophysiology of disease, with the objective to find more efficient anti-cancer therapies. We would like to warmly thank the researchers with whom we are collaborating Read more…
Biomimesys
Development of cerebral in vitro 3D models: update about Veronique’s PhD thesis
There are 90% of failure in clinical trials, mainly due to safety and efficiency issues. In particular, the central nervous system is involved in 34% of failure in clinical trials, but only in 7% of failure in preclinical trials (Cook et al., 2014). That points a lack of relevance in Read more…
Biomimesys
Thomas joins us to work on breast cancer
It’s pleasure to welcome Thomas in our team. After a four-month internship at the CrCHUM (Centre de recherche du Centre Hospitalier de l’Université de Montréal, Canada) in the field of microfluidic personalized medicine for prostate cancer, he joined us in September for a six- months-internship, as part of his Master’s Read more…